<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0185-3325</journal-id>
<journal-title><![CDATA[Salud mental]]></journal-title>
<abbrev-journal-title><![CDATA[Salud Ment]]></abbrev-journal-title>
<issn>0185-3325</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0185-33252017000200071</article-id>
<article-id pub-id-type="doi">10.17711/sm.0185-3325.2017.010</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[An approach to the new psychoactive drugs phenomenon]]></article-title>
<article-title xml:lang="es"><![CDATA[Una aproximación al fenómeno de las nuevas drogas psicoactivas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[Helen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Arnau]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Mateos]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario del Henares Servicio de Psiquiatría ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Psiformación  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario Ramón y Cajal Centro de Salud Mental de San Blas ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario La Fe  ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>40</volume>
<numero>2</numero>
<fpage>71</fpage>
<lpage>82</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0185-33252017000200071&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0185-33252017000200071&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0185-33252017000200071&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background. The new psychoactive drugs (NPD) are those that represent a danger to public health and are not prohibited by conventions on international narcotics. The concept also includes new contexts and new routes of consumption as well as novel ways of distribution, notably Internet. The risks associated with NPD consumption are largely unknown to users and to health care providers.  Objective. To integrate the existing evidence regarding the main NPD in terms of description, epidemiology, psychopharmacology, medical complications and psychoactive effects.  Method. To review relevant and updated clinical information on NPD obtained from specialized books and indexed scientific journals (PubMed/Medline, Google Scholar, Scopus), as well as official documents edited by international organizations dedicated to the epidemiologic analysis of drug abuse and Internet websites and forums managed by psychoactive substance users.  Results. Aspects of clinical and pharmacological interest are described comprehensively, together with epidemiological data and risks associated to the consumption of the most relevant NPD: synthetic cannabinoids, synthetic cathinones, NBOMe series, indoleamines, piperazines, hallucinogenic mushrooms (Psilocybe SP.), synthetic opioids, plant products (khat, kratom, Salvia divinorum, ayahuasca) and dissociative anesthetics.  Discussion and conclusion. The emergence of the NPD is a phenomenon on the rise with important consequences for public health. Learning about new trends in drug consumption and its potential risks should be essential for the medical professional. New research is needed in order to understand the phenomenon of the NPD and its pharmacological, clinical and legal implications.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes. Las nuevas drogas psicoactivas (NDP) son aquellas que, aun cuando representan un peligro para la salud pública, no están prohibidas por los acuerdos internacionales sobre narcóticos. La noción incluye también nuevos contextos de usos, nuevas formas de administración y nuevas vías de distribución, entre las que destaca Internet. Los riesgos asociados al consumo de NDP son en gran medida desconocidos por los usuarios y el personal de salud.  Objetivo. Integrar la información existente sobre las principales NDP en cuanto a su descripción, psicofarmacología, epidemiología, efectos psicoactivos y complicaciones médicas descritas.  Método. Revisión de la información actualizada de relevancia clínica sobre las NDP obtenida de libros especializados y revistas científicas indexadas (PubMed/Medline, Google Scholar, Scopus); de documentos oficiales de organismos internacionales dedicados a la epidemiología del consumo de drogas, y de portales y foros en Internet gestionados por usuarios de sustancias psicoactivas.  Resultados. Se describen de manera detallada aspectos de interés clínico y farmacológico, así como datos epidemiológicos y riesgos asociados al consumo de las NDP más relevantes: cannabinoides sintéticos, catinonas sintéticas, serie de los NBOMe, indolaminas, piperazinas, hongos alucinógenos (Psilocybe sp.), opioides sintéticos, productos vegetales (khat, kratom, Salvia divinorum, ayahuasca) y anestésicos disociativos.  Discusión y conclusión. El surgimiento de las NDP es un fenómeno en auge con importantes consecuencias en la salud pública. Se hace imprescindible para el profesional médico conocer las nuevas tendencias en el consumo y los riesgos potenciales del mismo. Son necesarias también nuevas investigaciones para comprender el fenómeno de las NDP y sus implicaciones farmacológicas, clínicas y legales.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Spice]]></kwd>
<kwd lng="en"><![CDATA[cathinone]]></kwd>
<kwd lng="en"><![CDATA[psychoactive drugs]]></kwd>
<kwd lng="en"><![CDATA[khat]]></kwd>
<kwd lng="en"><![CDATA[opioids]]></kwd>
<kwd lng="es"><![CDATA[Spice]]></kwd>
<kwd lng="es"><![CDATA[catinona]]></kwd>
<kwd lng="es"><![CDATA[drogas psicoactivas]]></kwd>
<kwd lng="es"><![CDATA[khat]]></kwd>
<kwd lng="es"><![CDATA[opioides]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Aziz]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Ethnopharmacology]]></source>
<year>2012</year>
<volume>141</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>446-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A fatal poisoning involving 25C-NBOMe]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andreasen]]></surname>
<given-names><![CDATA[M. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Telving]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosendal]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Eg]]></surname>
<given-names><![CDATA[M. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Hasselstrøm]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[L. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Science International]]></source>
<year>2015</year>
<volume>251</volume>
<page-range>e1-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Appendino]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Minassi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Taglialatela-Scafati]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Natural Product Reports]]></source>
<year>2014</year>
<volume>31</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>880-904</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The hallucinogenic world of tryptamines: an updated review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos]]></surname>
<given-names><![CDATA[Mde L.]]></given-names>
</name>
<name>
<surname><![CDATA[Guedes-de-Pinho]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Toxicology]]></source>
<year>2015</year>
<volume>89</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1151-73</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of legal high packages containing synthetic cathinones]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Valente]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dias-da-Silva]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Guedes de Pinho]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Toxicology]]></source>
<year>2015</year>
<volume>89</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>757-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arbo]]></surname>
<given-names><![CDATA[M. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Melega]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Stöber]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Schug]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rempel]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Rahnenführer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hengstler]]></surname>
<given-names><![CDATA[J. G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Toxicology]]></source>
<year>2016</year>
<volume>90</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3045-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baumann]]></surname>
<given-names><![CDATA[M. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ayestas]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Partilla]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sink]]></surname>
<given-names><![CDATA[J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Shulgin]]></surname>
<given-names><![CDATA[A. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Daley]]></surname>
<given-names><![CDATA[P. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Cozzi]]></surname>
<given-names><![CDATA[N. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2012</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1192-203</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bersani]]></surname>
<given-names><![CDATA[F. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Albano]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Valeriani]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Santacroce]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Bolzan-Mariotti-Posocco]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[BioMed Research International]]></source>
<year>2014</year>
<volume>2014</volume>
<page-range>734749</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bileck]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferk]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Serori]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Koller]]></surname>
<given-names><![CDATA[V. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Muqaku]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Haslberger]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Knasmüller]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Toxicology]]></source>
<year>2016</year>
<volume>90</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1369-82</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The serotonin syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[E. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[The New England Journal of Medicine]]></source>
<year>2005</year>
<volume>352</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1112-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carhart-Harris]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bolstridge]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rucker]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[C. M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Erritzoe]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaelen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Lancet Psychiatry]]></source>
<year>2016</year>
<volume>3</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>619-27</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castaneto]]></surname>
<given-names><![CDATA[M. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Gorelick]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Desrosiers]]></surname>
<given-names><![CDATA[N. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Pirard]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Huestis]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2014</year>
<volume>144</volume>
<page-range>12-41</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of synthetic cannabinoids in patients with psychotic disorders: case series]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Celofiga]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Koprivsek]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Klavz]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Dual Diagnosis]]></source>
<year>2014</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>168-73</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AH-7921: a new synthetic opioid of abuse]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coppola]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mondola]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Review]]></source>
<year>2015</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>109-10</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[From &#8220;Special K&#8221; to &#8220;Special M&#8221;: the evolution of the recreational use of ketamine and methoxetamine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Assi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[CNS Neuroscience &amp; Therapeutics]]></source>
<year>2013</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>454-60</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Assi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Simonato]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Corkery]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Bersani]]></surname>
<given-names><![CDATA[F. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Demetrovics]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Psychopharmacology]]></source>
<year>2013</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>317-23</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiology of adolescent Salvia divinorum use in Canada]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currie]]></surname>
<given-names><![CDATA[C. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2013</year>
<volume>128</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>166-70</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dargan]]></surname>
<given-names><![CDATA[P. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[D. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Novel Psychoactive Substances: Classification, Pharmacology and Toxicology]]></source>
<year>2013</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[e-Psychonauts: conducting research in online drug forum communities]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Deluca]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<collab>Psychonaut Web Mapping Group</collab>
<source><![CDATA[Journal of Mental Health]]></source>
<year>2012</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>386-94</page-range><publisher-loc><![CDATA[Abingdon, England ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Forti]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sallis]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Allegri]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Trotta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferraro]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Stilo]]></surname>
<given-names><![CDATA[S. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Schizophrenia Bulletin]]></source>
<year>2014</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1509-17</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Arnau-Ramírez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Mateos]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Nuevas Drogas Psicoactivas]]></source>
<year>2015</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Entheos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Panorama actual en el uso de drogas emergentes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Arnau-Ramírez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Rabito-Alcón]]></surname>
<given-names><![CDATA[M. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Correas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Health and Addictions: Salud Y Drogas]]></source>
<year>2014</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-58</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New Psychoactive Drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Arnau Ramírez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Mateos]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Adicciones]]></source>
<year>2015</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>231-2</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. Case Reports]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Arnau]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Mateos]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychiatry]]></source>
<year>2016</year>
<volume>2016</volume>
<page-range>8379562</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Uso de sustancias psicoactivas en la era de Internet Psychoactive substance use in the Internet era]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Arnau-Ramírez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Frenzi-Rabito-Alcón]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Correas-Lauffer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Revista de Patología Dual]]></source>
<year>2014</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Khoury]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sahakian]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Psychoactive Drugs]]></source>
<year>2015</year>
<volume>47</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>286-92</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[First reported fatalities associated with the &#8220;research chemical&#8221; 2-methoxydiphenidine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[S. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[S. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Wallach]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kavanagh]]></surname>
<given-names><![CDATA[P. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Analytical Toxicology]]></source>
<year>2015</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>287-93</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hallucinogen persisting perception disorder after psilocybin consumption: a case study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espiard]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Lecardeur]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Abadie]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Halbecq]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Dollfus]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Psychiatry]]></source>
<year>2005</year>
<volume>20</volume>
<numero>5-6</numero>
<issue>5-6</issue>
<page-range>458-60</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="book">
<collab>European Monitoring Centre for Drugs and Drug Addiction</collab>
<source><![CDATA[New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015)]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Luxembourg ]]></publisher-loc>
<publisher-name><![CDATA[Office of the European Union]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The behavioral pharmacology of hallucinogens]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fantegrossi]]></surname>
<given-names><![CDATA[W. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Murnane]]></surname>
<given-names><![CDATA[K. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Reissig]]></surname>
<given-names><![CDATA[C. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biochemical Pharmacology]]></source>
<year>2008</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-33</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Beyond THC: The New Generation of Cannabinoid Designer Drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fattore]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Fratta]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Frontiers in Behavioral Neuroscience]]></source>
<year>2011</year>
<volume>5</volume>
<numero>60</numero>
<issue>60</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inhibition of monoamine oxidase activity by cannabinoids. Naunyn-Schmiedeberg&#8217;s]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisar]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Pharmacology]]></source>
<year>2010</year>
<volume>381</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>563-72</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Drogas emergentes: una perspectiva médico-legal]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Repetto]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Soria]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Med Legal]]></source>
<year>2011</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>76-82</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giné]]></surname>
<given-names><![CDATA[C. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[I. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Vilamala]]></surname>
<given-names><![CDATA[M. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Testing and Analysis]]></source>
<year>2014</year>
<volume>6</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>819-24</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220; FLAKKA &#8221;:Una nueva droga psicoactiva en España.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Arnau]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Mateos]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Revista de Patología Dual]]></source>
<year>2015</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>6-7</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Khat use and monitoring drug use in Europe: the current situation and issues for the future]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Sedefov]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Gallegos]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Noor]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Royuela]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Ethnopharmacology]]></source>
<year>2010</year>
<volume>132</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>578-83</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Spice&#8221; and &#8220;K2&#8221; herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gunderson]]></surname>
<given-names><![CDATA[E. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Haughey]]></surname>
<given-names><![CDATA[H. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ait-Daoud]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[A. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[C. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[The American Journal on Addictions]]></source>
<year>2012</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>320-6</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recent advances in the neuropsychopharmacology of serotonergic hallucinogens]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halberstadt]]></surname>
<given-names><![CDATA[A. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Behavioural Brain Research]]></source>
<year>2015</year>
<volume>277</volume>
<page-range>99-120</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasler]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Grimberg]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Benz]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Vollenweider]]></surname>
<given-names><![CDATA[F. X.]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychopharmacology]]></source>
<year>2004</year>
<volume>172</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>145-56</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[MT-45, a new psychoactive substance associated with hearing loss and unconsciousness]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helander]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bäckberg]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2014</year>
<volume>52</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>901-4</page-range><publisher-loc><![CDATA[Philadelphia, Pa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helander]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Bäckberg]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2015</year>
<volume>53</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>446-53</page-range><publisher-loc><![CDATA[Philadelphia, Pa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermanns-Clausen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kneisel]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Szabo]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Auwärter]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Addiction]]></source>
<year>2013</year>
<volume>108</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>534-44</page-range><publisher-loc><![CDATA[Abingdon, England ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacological aspects of the chewing of khat leaves]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalix]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Braenden]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacological Reviews]]></source>
<year>1985</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>149-64</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxicology and management of novel psychoactive drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kersten]]></surname>
<given-names><![CDATA[B. P.]]></given-names>
</name>
<name>
<surname><![CDATA[McLaughlin]]></surname>
<given-names><![CDATA[M. E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Pharmacy Practice]]></source>
<year>2015</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-65</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Methoxetamine (MXE)--a phenomenological study of experiences induced by a &#8220;legal high&#8221; from the internet]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjellgren]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jonsson]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Psychoactive Drugs]]></source>
<year>2013</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>276-86</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[25I-NBOMe related death in Australia: a case report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kueppers]]></surname>
<given-names><![CDATA[V. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Cooke]]></surname>
<given-names><![CDATA[C. T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Science International]]></source>
<year>2015</year>
<volume>249</volume>
<page-range>e15-8</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyriakou]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Marinelli]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Frati]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Santurro]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Afxentiou]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zaami]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Busardo]]></surname>
<given-names><![CDATA[F. P.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Review for Medical and Pharmacological Sciences]]></source>
<year>2015</year>
<volume>19</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>3270-81</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="book">
<collab>Laboratory and Scientific Section, UNODC</collab>
<source><![CDATA[The challenge of new psychoactive substances]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Vienna, Austria ]]></publisher-loc>
<publisher-name><![CDATA[United Nations Office on Drugs and Crime]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Increase in reported adverse health effects related to synthetic cannabinoids use - United States]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Schier]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Wolkin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[MMWR]]></source>
<year>2015</year>
<volume>64</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>618-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawn]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Barratt]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Horne]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Winstock]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2014</year>
<volume>28</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>780-8</page-range><publisher-loc><![CDATA[Oxford, England ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The interest in eight new psychoactive substances before and after scheduling]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ledberg]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2015</year>
<volume>152</volume>
<page-range>73-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Arnau]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Clemente]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pubill]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Escubedo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Camarasa]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[British Journal of Pharmacology]]></source>
<year>2012</year>
<volume>167</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>407-20</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McElrath]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Neill]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[The International Journal on Drug Policy]]></source>
<year>2011</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-7</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Odenwald]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Neuner]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Schauer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Elbert]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Catani]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lingenfelder]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Rockstroh]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Medicine]]></source>
<year>2005</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ott]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacotheon]]></source>
<year>2000</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Los Libros de la Liebre de Marzo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Synthetic cannabinoid use in a nationally representative sample of US high school seniors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palamar]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2015</year>
<volume>149</volume>
<page-range>194-202</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poklis]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Devers]]></surname>
<given-names><![CDATA[K. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Arbefeville]]></surname>
<given-names><![CDATA[E. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Houston]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Poklis]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Science International]]></source>
<year>2014</year>
<volume>234</volume>
<page-range>e14-20</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riba]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Valle]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Urbano]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Yritia]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Morte]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Barbanoj]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Pharmacology and Experimental Therapeutics]]></source>
<year>2003</year>
<volume>306</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-83</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vegetables as new psychoactive drugs: a narrative review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Salgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Arnau-Ramírez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Mateos]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Dolengevich-Segal]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Medwave]]></source>
<year>2016</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e6372</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santacroce]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Martinotti]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Bersani]]></surname>
<given-names><![CDATA[F. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Valeriani]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Di-Giannantonio]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Psychopharmacology]]></source>
<year>2015</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>265-71</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mephedrone (4-methylmethcathinone; &#8220;meow meow&#8221;): chemical, pharmacological and clinical issues]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Albanese]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Fergus]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Stair]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Deluca]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Corazza]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Ghodse]]></surname>
<given-names><![CDATA[A. H.]]></given-names>
</name>
</person-group>
<collab>ReDNet Research Groups</collab>
<source><![CDATA[Psychopharmacology]]></source>
<year>2011</year>
<volume>214</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>593-602</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Novel psychoactive substances of interest for psychiatry]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Orsolini]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Duccio-Papanti]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Corkery]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[World Psychiatry]]></source>
<year>2015</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-26</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Legal highs&#8221; on the net-Evaluation of UK-based Websites, products and product information]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Feinmann]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Science International]]></source>
<year>2011</year>
<volume>206</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>92-7</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schultes]]></surname>
<given-names><![CDATA[R. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Plantas de los Dioses]]></source>
<year>2000</year>
<publisher-loc><![CDATA[México DF ]]></publisher-loc>
<publisher-name><![CDATA[Fondo de Cultura Económica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shulgin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[PiHKAL: A Chemical Love Story]]></source>
<year>1991</year>
<publisher-loc><![CDATA[California ]]></publisher-loc>
<publisher-name><![CDATA[Transform Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shulgin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[TiHKAL: The Continuation]]></source>
<year>1997</year>
<publisher-loc><![CDATA[California ]]></publisher-loc>
<publisher-name><![CDATA[Transform Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Verney]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Dargan]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[D. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2015</year>
<volume>53</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>54-9</page-range><publisher-loc><![CDATA[Philadelphia, Pa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[C. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Vicknasingam]]></surname>
<given-names><![CDATA[B. K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2014</year>
<volume>139</volume>
<page-range>132-7</page-range></nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The claustrum&#8217;s proposed role in consciousness is supported by the effect and target localization of Salvia divinorum]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stiefel]]></surname>
<given-names><![CDATA[K. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Merrifield]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Holcombe]]></surname>
<given-names><![CDATA[A. O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Frontiers in Integrative Neuroscience]]></source>
<year>2014</year>
<volume>8</volume>
<numero>20</numero>
<issue>20</issue>
</nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stolt]]></surname>
<given-names><![CDATA[A.-C.]]></given-names>
</name>
<name>
<surname><![CDATA[Schröder]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Neurath]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Grecksch]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Höllt]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychopharmacology]]></source>
<year>2014</year>
<volume>231</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-25</page-range></nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[M. H. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Ching]]></surname>
<given-names><![CDATA[C. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Tsui]]></surname>
<given-names><![CDATA[M. S. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[F. K. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mak]]></surname>
<given-names><![CDATA[T. W. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2014</year>
<volume>52</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>561-5</page-range><publisher-loc><![CDATA[Philadelphia, Pa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Krokodil&#8221;--a designer drug from across the Atlantic, with serious consequences]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thekkemuriyi]]></surname>
<given-names><![CDATA[D. V.]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[S. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Pillai]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<source><![CDATA[The American Journal of Medicine]]></source>
<year>2014</year>
<volume>127</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e1-2</page-range></nlm-citation>
</ref>
<ref id="B73">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psilocybin--summary of knowledge and new perspectives]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tyl&#353;]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Pálení&#269;ek]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Horá&#269;ek]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[European Neuropsychopharmacology]]></source>
<year>2014</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>342-56</page-range></nlm-citation>
</ref>
<ref id="B74">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uchiyama]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Kawamura]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kikura-Hanajiri]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Goda]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Science International]]></source>
<year>2013</year>
<volume>227</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>21-32</page-range></nlm-citation>
</ref>
<ref id="B75">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psychoactive natural products: overview of recent developments]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ujváry]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Annali dell&#8217;Istituto Superiore Di Sanita]]></source>
<year>2014</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-27</page-range></nlm-citation>
</ref>
<ref id="B76">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Word of mouse&#8221;: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van-Hout]]></surname>
<given-names><![CDATA[M. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Hearne]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Psychoactive Drugs]]></source>
<year>2015</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-41</page-range></nlm-citation>
</ref>
<ref id="B77">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Spice drugs as a new trend: mode of action, identification and legislation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vardakou]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Pistos]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Spiliopoulou]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Toxicology Letters]]></source>
<year>2010</year>
<volume>197</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>157-62</page-range></nlm-citation>
</ref>
<ref id="B78">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chemistry, pharmacology, and toxicology of khat (catha edulis forsk): a review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wabe]]></surname>
<given-names><![CDATA[N. T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Addiction &amp; Health]]></source>
<year>2011</year>
<volume>3</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>137-49</page-range></nlm-citation>
</ref>
<ref id="B79">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pathological findings in 2 cases of fatal 25I-NBOMe toxicity]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walterscheid]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[G. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[A. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Gonsoulin]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H.-H.]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[L. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[The American Journal of Forensic Medicine and Pathology]]></source>
<year>2014</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>20-5</page-range></nlm-citation>
</ref>
<ref id="B80">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The impact of the prohibition of benzylpiperazine (BZP) &#8220;legal highs&#8221; on the prevalence of BZP, new legal highs and other drug use in New Zealand]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilkins]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Sweetsur]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2013</year>
<volume>127</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>72-80</page-range></nlm-citation>
</ref>
<ref id="B81">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winkelman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Current Drug Abuse Reviews]]></source>
<year>2014</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-16</page-range></nlm-citation>
</ref>
<ref id="B82">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of use and acute toxicity associated with the use of NBOMe drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[D. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sedefov]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Dargan]]></surname>
<given-names><![CDATA[P. I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Toxicology]]></source>
<year>2015</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>85-92</page-range><publisher-loc><![CDATA[Philadelphia, Pa. ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B83">
<nlm-citation citation-type="confpro">
<collab>World Health Organization</collab>
<source><![CDATA[Alpha methyltryptamine (AMT). Critical Review]]></source>
<year>2014</year>
<conf-name><![CDATA[ WHO Expert Committee on Drug Dependence]]></conf-name>
<conf-loc>Geneva, Suiza. </conf-loc>
</nlm-citation>
</ref>
<ref id="B84">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Is there something more about synthetic cannabinoids?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yip]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Dart]]></surname>
<given-names><![CDATA[C. R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Toxicol]]></source>
<year>2014</year>
<volume>32</volume>
<page-range>340-1</page-range></nlm-citation>
</ref>
<ref id="B85">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Next generation of novel psychoactive substances on the horizon - A complex problem to face]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zawilska]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Andrzejczak]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2015</year>
<volume>157</volume>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B86">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Withdrawal phenomena and dependence syndrome after the consumption of &#8220;spice gold&#8221;]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[U. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Winkelmann]]></surname>
<given-names><![CDATA[P. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Pilhatsch]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Nees]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Spanagel]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Deutsches Arzteblatt International]]></source>
<year>2009</year>
<volume>106</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>464-7</page-range></nlm-citation>
</ref>
<ref id="B87">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[25C-NBOMe--new potent hallucinogenic substance identified on the drug market]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuba]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Seku&#322;a]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Buczek]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Forensic Science International]]></source>
<year>2013</year>
<volume>227</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>7-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
